Ibogaine has been associated with QT interval prolongation, an ECG finding that can signal delayed ventricular repolarization. The concern is not a theoretical label: a prolonged QT can create conditions in which a dangerous polymorphic ventricular rhythm, torsade de pointes, becomes more likely. The long QT syndrome overview is useful background for understanding why clinicians pay attention to the interval even when a person does not feel palpitations.
For people comparing high-volume treatment operations, the important questions are objective: what is measured before dosing, how often it is rechecked, who reads the data, which medications and substances are reconciled, and what happens when an ECG or laboratory value changes. Those questions sit alongside broader concerns in the Ambio safety checklist, rather than being replaced by a general assurance that monitoring is available.
Cardiac screening is not a promise of safety. It is a way to identify known risk signals, document uncertainty, and decide whether a setting can recognize and respond to a change.
Published reports and case series describe adverse cardiac events and fatalities in the context of ibogaine exposure, often with multiple possible contributors such as co-exposures, withdrawal, underlying disease, or electrolyte disturbance. The evidence base is limited by incomplete reporting and the absence of large controlled safety datasets. That uncertainty is a reason to scrutinize claims, not a reason to assume either zero risk or a single cause in every case.